ArticleData in brief2025
Brain lesion MRI and co-related MRS spectroscopy dataset.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers of Treatment Response in Paediatric Medulloblastoma.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Analysing brain lesions of various aetiologies necessitates imaging data with subsequent diagnostic techniques that may enable concomitant visualization of spatial anatomical entities, and aberrant molecular behaviour. To fulfil this necessity, several image types and modalities should be collected. This dataset includes MRI (Magnetic Resonance Imaging) with three modalities T2-FLAIR, T1-weighted pre- and post-contrast along with Magnetic Resonance Spectroscopy (MRS) scans for 55 patients. All patients were diagnosed with neoplastic and non-neoplastic brain lesions. T2-FLAIR and contrast-enhanced T1 MRI modalities reveal structural differences in lesions, whereas MRS affords metabolite information. In addition to the imaging data, patient metadata such as age, gender, and expert diagnosis- classify brain lesions into two types: neoplastic (low or high grade) and non-neoplastic. The data were collected between 2023 and 2024 at Al-Andalus Oncology Centre in Baghdad, Iraq, and are publicly available. This dataset is essential as it combines conventional (MRI) and metabolic (MRS) imaging with expert diagnosis information. This dataset is significant as it includes MRI and MRS images along with expert diagnoses information, offering high reuse potential in medical imaging and diagnostic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.